Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.PALI · Entity 5803 | Chief Medical Officer | March 29, 2022 | March 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date March 29, 2022 · Filed March 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2022-03-29 transaction · row 1
1 source rowRow 1 · 2022-03-29 · Purchase · Acquired 15,000 · Balance 15,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2022 Filed Mar 31, 2022 12:31 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 15,000 | $1.14 | $17,092.50 |
DisclosureSEC source: 0001209191-22-021681 · doc4.xml · nonDerivative · entry 1 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:54 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (right to buy) · Derivative | 32,400 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001209191-22-011853 · doc4.xml · derivative · entry 1 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,400 Underlying: Common Stock · 32,400 shares Expires 2032-02-16 F1 · derivative.exercise_date: 1/12th of the shares underlying the Stock Option shall vest and become exercisable on each three-month anniversary of the vesting commencement date and if there is no corresponding day, the last day of the month. Read SEC document |
| November 18, 2021 Filed Feb 10, 2022 23:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (right to buy) · Derivative | 39,294 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-008596 · doc4.xml · derivative · entry 1 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,294 Underlying: Common Stock · 39,294 shares Expires 2031-11-17 F1 · derivative.exercise_date: 1/12th of the shares underlying the Stock Option shall vest and become exercisable on each three-month anniversary of the vesting commencement date and if there is no corresponding day, the last day of the month. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 2,800 | Not disclosed Strike: $26.85 | Not disclosed |
DisclosureSEC source: 0001209191-21-029066 · doc4.xml · derivative · entry 5 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 2,800 shares Expires 2030-02-19 F8 · price: Received in the Merger in exchange for a stock option to acquire 103,000 shares of LBS common stock for $0.73 per share. F1 · derivative.exercise_date: The stock option vested in four equal quarterly installments from the vesting commencement date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 1,962 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029066 · doc4.xml · derivative · entry 4 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2029-03-22 F7 · price: Received in the Merger in exchange for a stock option to acquire 72,200 shares of LBS common stock for $1.12 per share. F1 · derivative.exercise_date: The stock option vested in four equal quarterly installments from the vesting commencement date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 5,084 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029066 · doc4.xml · derivative · entry 3 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,084 Underlying: Common Stock · 5,084 shares Expires 2029-03-22 F6 · price: Received in the Merger in exchange for a stock option to acquire 187,000 shares of LBS common stock for $1.12 per share. F5 · derivative.exercise_date: The stock option vests according to the following schedule: 33% of the shares underlying the option vests on grant date and the remaining 67% vests in eight equal quarterly installments thereafter beginning on March 31, 2019. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 20,391 | Not disclosed Strike: $53.33 | Not disclosed |
DisclosureSEC source: 0001209191-21-029066 · doc4.xml · derivative · entry 2 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,391 Underlying: Common Stock · 20,391 shares Expires 2028-07-24 F4 · price: Received in the Merger in exchange for a stock option to acquire 750,000 shares of LBS common stock for $1.45 per share. F3 · derivative.exercise_date: The stock option vests according to the following schedule: 17% of the shares underlying the option vests on grant date and the remaining 83% vests in 10 quarterly installments thereafter beginning on September 30, 2018. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:46 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 5,438 | Not disclosed Strike: $27.59 | Not disclosed |
DisclosureSEC source: 0001209191-21-029066 · doc4.xml · derivative · entry 1 Dawson Michael John · CIK 0001849790 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,438 Underlying: Common Stock · 5,438 shares Expires 2027-02-10 F2 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of Leading BioSciences, Inc. ("LBS") for $0.75 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc. F1 · derivative.exercise_date: The stock option vested in four equal quarterly installments from the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.